attention%20deficit_hyperactivity%20disorder
ATTENTION DEFICIT/HYPERACTIVITY DISORDER
Attention deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by the presence of impairing levels of inattention, disorganization and/or hyperactivity-impulsivity.
Symptoms that suggest ADHD include hyperactivity, acting without thinking, inattention/daydreaming, fidgety, restless, excessive talking, aggressive behavior, academic underachievement, disorganized and has difficulty in completing tasks.

Follow Up

  • Initially, monitor on a monthly basis until consistent optimal response is noted
    • Then every 3 months in the 1st year of treatment
  • Subsequent follow-up will depend on patient’s response, adherence to treatment strategy, presence of associated conditions
    • Recommended is at least 2 times a year
  • Monitor treatment outcomes and adverse effects (cardiovascular effects, development of tics or seizures, sexual dysfunction, changes in sleep pattern, worsening behavior, stimulant misuse and diversion) by gathering information from parents, teachers and the child
  • Monitor core symptoms using DSM-5-based ADHD rating scales (eg Vanderbilt ADHD follow-up scales)
  • Re-evaluate the patient when treatment and management plan does not meet desired outcomes
  • Reassess patient at school-leaving age to check for continuity of care into adulthood 
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, Yesterday

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 2 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
6 days ago
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.